Skip to content

Study · Randomized controlled trial · n = 3,045 · 2018

6 results

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.

Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B

Diabetes, obesity & metabolism7 Jun 2018Cited by 54 (Europe PMC)

PMID29687620 (opens in a new tab)PMCIDPMC6099273 (opens in a new tab)DOI10.1111/dom.13331 (opens in a new tab)PepBankPUB-29687620
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In non-elderly adults with type 2 diabetes, semaglutide 0.5 and 1.0 mg lowered HbA1c more than pooled comparators.

    In plain wordsIn adults under 65 with type 2 diabetes, semaglutide lowered HbA1c more than comparator drugs or placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change in non-elderly patients
    Study

    n = 3,045

    Comparator
    Pooled comparators (placebo, sitagliptin, exenatide, insulin)
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    HbA1c change
    1.2 to 1.5%
    semaglutide 0.5 mg, non-elderly
    HbA1c change
    1.5 to 1.9%
    semaglutide 1.0 mg, non-elderly
    HbA1c change
    0 to 0.9%
    comparators, non-elderly

    Source sentences

    Summary
    Mean HbA1c decreased from baseline by 1.2%-1.5% and 1.5%-1.9% vs 0%-0.9% (non-elderly, n = 3045) and by 1.3%-1.5% and 1.2%-1.8% vs 0.2%-1.0% (elderly, n = 854) with semaglutide 0.5 and 1.0 mg vs comparators.
    1 context sentence
    Summary · context
    Patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In elderly adults with type 2 diabetes, semaglutide 0.5 and 1.0 mg lowered HbA1c more than pooled comparators.

    In plain wordsIn adults aged 65 and over with type 2 diabetes, semaglutide lowered HbA1c more than comparator drugs or placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change in elderly patients
    Study

    n = 854

    Comparator
    Pooled comparators (placebo, sitagliptin, exenatide, insulin)
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    HbA1c change
    1.3 to 1.5%
    semaglutide 0.5 mg, elderly
    HbA1c change
    1.2 to 1.8%
    semaglutide 1.0 mg, elderly
    HbA1c change
    0.2 to 1%
    comparators, elderly

    Source sentences

    Summary
    Mean HbA1c decreased from baseline by 1.2%-1.5% and 1.5%-1.9% vs 0%-0.9% (non-elderly, n = 3045) and by 1.3%-1.5% and 1.2%-1.8% vs 0.2%-1.0% (elderly, n = 854) with semaglutide 0.5 and 1.0 mg vs comparators.
    1 context sentence
    Summary · context
    Patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    Semaglutide produced similar reductions in mean body weight in non-elderly and elderly patients with type 2 diabetes.

    In plain wordsSemaglutide lowered body weight by similar amounts in younger and older adults with type 2 diabetes.

    Peptide
    Semaglutide
    Outcome
    No significant changeBody weight change by age group
    Study

    n: not reported in source

    Comparator
    Non-elderly patients
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Similar reductions from baseline in mean body weight with semaglutide occurred in both age groups.
    1 context sentence
    Summary · context
    Patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin.
  4. 04HumanRandomized controlled trialSafety outcome

    Similar proportions of elderly and non-elderly patients had adverse events with semaglutide.

    In plain wordsSimilar proportions of older and younger adults had side effects with semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeProportion with adverse events by age group
    Study

    n: not reported in source

    Comparator
    Non-elderly patients
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Similar proportions of patients experienced adverse events
    1 context sentence
    Summary · context
    Patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin.
  5. 05HumanRandomized controlled trialSafety outcome

    Premature treatment discontinuations were higher in elderly than in non-elderly patients treated with semaglutide.

    In plain wordsOlder adults stopped semaglutide early more often than younger adults.

    Peptide
    Semaglutide
    Outcome
    IncreasePremature treatment discontinuation by age group
    Study

    n: not reported in source

    Comparator
    Non-elderly patients
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    premature treatment discontinuations were higher in elderly vs non-elderly patients.
    1 context sentence
    Summary · context
    Patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin.
  6. 06HumanRandomized controlled trialSafety outcome

    Semaglutide did not increase the risk of severe or blood glucose-confirmed hypoglycaemia versus comparators in either age group.

    In plain wordsSemaglutide did not raise the risk of low blood sugar compared with other treatments in younger or older adults.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere or blood glucose-confirmed hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Pooled comparators (placebo, sitagliptin, exenatide, insulin)
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No increased risk of severe or blood glucose-confirmed hypoglycaemia was seen with semaglutide vs comparators between age groups.
    1 context sentence
    Summary · context
    Patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials5

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

5 trials · 1 ongoing · 4 completed · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT06072963

COMMETS- Combination MCI Metabolic Syndrome

Rutgers, The State University of New Jerseyn = 8030 Jan 2024 to est. 1 Dec 2028

Alzheimer Disease · Mild Cognitive Impairment · Metabolic Syndrome

Trial pageClinicalTrials.govUpdated 27 Jul 2026
CompletedPhase 3Results postedNCT02305381

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3971 Dec 2014 to 21 Nov 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 11 Jun 2019
CompletedPhase 3Results postedNCT02128932

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,0894 Aug 2014 to 3 Sept 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 13 Jun 2019
CompletedPhase 3Results postedNCT02054897

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3883 Feb 2014 to 8 May 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 12 Jun 2019
CompletedPhase 3Results postedNCT01885208

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 8132 Dec 2013 to 13 Jul 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 13 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.